The profitability of IMMUNOVANT, INC. over the past 8 years
Chart IMMUNOVANT, INC.: net income, fiscal 2019–2026 Open the chart →IMMUNOVANT, INC. reported a net loss of $505.61M in fiscal 2026, the latest fiscal year on file. It reported a loss in all 8 years shown.
Year by year
| Fiscal year | Net income |
|---|---|
| 2026ended Mar 31, 2026 | -$505.61M |
| 2025ended Mar 31, 2025 | -$413.84M |
| 2024ended Mar 31, 2024 | -$259.34M |
| 2023ended Mar 31, 2023 | -$210.96M |
| 2022ended Mar 31, 2022 | -$156.73M |
| 2021ended Mar 31, 2021 | -$107.43M |
| 2020ended Mar 31, 2020 | -$66.39M |
| 2019ended Mar 31, 2019 | -$28.6M |
Fiscal years as IMMUNOVANT, INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on IMMUNOVANT, INC.
- The cash flow of IMMUNOVANT, INC.
- The debt of IMMUNOVANT, INC.
- All of IMMUNOVANT, INC.'s financials, charted
Companies of a similar size
- CVICVR ENERGY, INC
- EPRTEssential Properties Realty Trust, Inc.
- CACCCREDIT ACCEPTANCE CORP
- MKTXMARKETAXESS HOLDINGS INC
- TEXTerex Corporation
Not investment advice. This page shows what IMMUNOVANT, INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.